Qingsong Health (02661) Surges Over 9% to Hit New High, Cumulative Gain Nears 230% Since IPO, Synergy Between Health and Insurance Services Validated

Stock News01-02

Qingsong Health (02661) rose more than 9%, reaching a high of HK$74.8, representing a gain of nearly 230% compared to its IPO price of HK$22.68. As of writing, the stock was up 8.83% to HK$74.6, with a turnover of HK$25.98 million. A research report from Guotou Securities International noted that Qingsong Health's primary businesses are health-related and insurance-related solutions. The company began its foray into insurance-related services in 2016, and as of June 30, 2025, these services cover 58 insurance company partners, reaching 26.2 million policyholders and generating cumulative premium income of RMB 5.4 billion. In 2023, the company launched digital marketing (science popularization services), primarily serving pharmaceutical companies by helping them connect with target user groups. The business is gradually transforming, continuously enriching its offerings with services such as digital medical research support and comprehensive health service packages. The report highlighted that the company possesses a certain ecosystem effect; approximately 30% of policyholders in 2024 were already clients of health-related services before purchasing insurance, demonstrating validated synergy between its health and insurance services. The customer retention rate for the insurance service-related business is relatively high, reaching 53% in the first half of 2025, while revenue from health services is showing rapid growth.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment